Near-Infrared Assay and Content Uniformity of Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Near-Infrared Assay and Content Uniformity of Tablets
Near-infrared (NIR) assay and content uniformity of tablets provide fast, accurate means of monitoring tablet production that are in step with FDA's process analytical technology initiative.The authors discuss the process for testing a newly released NIR tablet analyzer to determine instrument precision and accuracy using chlorpheniramine maleate tablets.The data show promising results that could relieve laboratory workload of high-performance liquid chromatography analysis and bring analysis closer to..


Pharmaceutical Technology


2. US Food and Drug Administration, Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, (FDA,Rockville, MD, Sept. 2004).

3. P.J. Larkin, E. Fruhling, and C. Longfellow, "Comparison of Fourier Transform (FT) and Grating Based NIR Spectrometers for Content Uniformity of Pharmaceutical Solid Dosage Forms," Am. Pharm. Review. 9 (6), 102–109 (2006).

4. Q. Ji et al., "Rapid Content Uniformity Determination of Low-Dose TCH 346 Tablets by NIR," Am. Pharm. Review 9 (5), 20–26 (2006).

5. R. Kramer, Chemometric Techniques for Quantitative Analysis, (Marcel Dekker, Inc., New York, NY, 1998).

6. K.R. Beebe, R.J. Pell, and M.B. Seasholtz, Chemometrics: A Practical Guide, (John Wiley & Sons, Hoboken, NJ, 1998).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here